TrumpRx Drug Site Launched After Brief Delay

The new government-run prescription drug portal, TrumpRx, is now live. It launched early this month after a delay from its original planned kick-off in January.

The site features 40 of the most popular – and expensive – branded medications from pharmaceutical companies that have worked out discounted pricing agreements with the White House. Those firms include 16 of the 17 largest manufacturers, five of whom have agreed to most-favored nation pricing. Firms AstraZeneca, Eli Lilly, Merck KGaA’s EMD Serona, Novo Nordisk, and Pfizer.

The featured medications comprise pills, injectables, nebulizers, and ointments. They include Ozempic and Wegovy for diabetes and obesity from Novo Nordisk, fertility drugs from EMD Serona, inhalers from AstraZeneca, eczema treatment Eucrisa from Pfizer, COPD medicine Bevespi Aerosphere, and others.

GLP-1 meds are priced dramatically lower than in 2025. Ozempic and injectable Wegovy costs are down from $1,028 and $1,379, respectively, to average prices of around $350, according to Becker’s Hospital Review. Some doses are as low as $199. The new Wegovy pill, which launched last month at $299 per month, is available at TrumpRx starting at $149. Eli Lilly’s competing Zepbound is as low as $299, down from over $1,000 per month. Drug dosage determines costs.

Patients do not buy drugs directly through the new site, but they can access discounted pricing in one of two ways:
•    Printable or digital TrumpRx coupons that are redeemable at retail pharmacies such as CVS.
•    Manufacturer-integrated tools and links built into TrumpRx.gov.

Although operational only for only a brief period, the drug discount program and website are not without their critics. Democratic Sen. Ron Wyden has described it as a “glorified coupon book.” Two professors from the University of Washington, including a former dean of pharmacy, have also been critical. They note in an opinion piece for Stat that while the site may save some Americans money on prescription drugs, it will be less beneficial for the roughly 85% of Americans who have current prescription drug insurance coverage.

In addition, it’s not yet known if those with insurance coverage were to purchase meds through TrumpRx whether their costs would count toward their insurance deductibles and annual out-of-pocket maximums.

Something else to consider is that about half of the drugs being discounted through TrumpRx already have generic equivalents, which are usually priced much lower the brand name drugs. That’s beneficial to those with and without insurance.

 

Source Link

Recommended Articles

IRS Unveils New Health Savings Account Limits For 2027

The IRS has released the 2027 contribution limits for health savings accounts, or HSAs, which offer triple-tax benefits for investors. Starting in 2027, the new HSA contribution limit will be $4,500 for self-only plans, up from $4,400 in 2026, based on the latest inflation adjustments. The HSA limit for family coverage will also rise in 2027. That cap will jump to $9,000, ...

Read More

Trump Backs HHS Overhaul Of Childhood Vaccine Schedule With New Order

President Trump is signing off on a decision from the Department of Health and Human Services (HHS) earlier this year to cut down on the number of required vaccinations for children. The president endorsed these adjusted immunization requirements in an executive order on Friday. Trump cited his administration’s commitment to “protecting religious liberty and parental authority” in the order. “Therefore, ...

Read More

China’s Rise in Drug Development Looms Over U.S.

For decades, an annual gathering of oncologists has featured drug trials that were run mainly at American and European hospitals.   But at this year’s meeting, which was held in Chicago over the weekend, the signs are everywhere of China’s ascendance as a powerhouse in drug development — and of the threat that many believe ...

Read More

UnitedHealthcare To Cut Pediatric Prior Authorization Requirements By Two-Thirds

UnitedHealth’s main health insurance business says it will reduce the number of prior authorization requirements for patients under 18 by about two-thirds by Dec. 31. UnitedHealthcare will cut prior authorization requirements for commercial health plans, as well as for Medicaid plans, and the shift will affect reviews for many diagnostic services and routine surgical procedures, ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square